Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCRαβ+ and CD19+ Depleted HSCT for Hematologic Diseases in Children and Young Adults
NCT04806347Phase 1Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2026
- Primary completion
- Jun 2029
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TCRαβ+/CD19+ depleted hematopoietic stem cells in sickle cell disease (SCD), beta thalassemia major, paroxysmal nocturnal hemoglobinuria (PNH) and 12 more, sponsored by University of Wisconsin–Madison. Primary endpoints: Incidence of grade III-IV acute graft-versus-host disease at 100 days, Incidence of extensive chronic GVHD at 2 years and 2 more. Started Nov 2026; status: recruiting.
02
Drugs
TCRαβ+/CD19+ depleted hematopoietic stem cells
03
Conditions
sickle cell disease (SCD)beta thalassemia majorparoxysmal nocturnal hemoglobinuria (PNH)myelodysplastic syndrome (MDS)acquired aplastic anemia (AAA)
Beyond the preview
Go deeper on NCT04806347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806347.